These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 8616867)

  • 41. Mutations of the ret protooncogene in German multiple endocrine neoplasia families: relation between genotype and phenotype. German Medullary Thyroid Carcinoma Study Group.
    Frank-Raue K; Höppner W; Frilling A; Kotzerke J; Dralle H; Haase R; Mann K; Seif F; Kirchner R; Rendl J; Deckart HF; Ritter MM; Hampel R; Klempa J; Scholz GH; Raue F
    J Clin Endocrinol Metab; 1996 May; 81(5):1780-3. PubMed ID: 8626834
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Point mutation within the tyrosine kinase domain of the RET proto-oncogene in multiple endocrine neoplasia type 2B and related sporadic tumours.
    Eng C; Smith DP; Mulligan LM; Nagai MA; Healey CS; Ponder MA; Gardner E; Scheumann GF; Jackson CE; Tunnacliffe A
    Hum Mol Genet; 1994 Feb; 3(2):237-41. PubMed ID: 7911697
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Diagnosis of multiple endocrine neoplasia [MEN] 2A, 2B and familial medullary thyroid cancer [FMTC] by multiplex PCR and heteroduplex analyses of RET proto-oncogene mutations.
    Kambouris M; Jackson CE; Feldman GL
    Hum Mutat; 1996; 8(1):64-70. PubMed ID: 8807338
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Germline dinucleotide mutation in codon 883 of the RET proto-oncogene in multiple endocrine neoplasia type 2B without codon 918 mutation.
    Gimm O; Marsh DJ; Andrew SD; Frilling A; Dahia PL; Mulligan LM; Zajac JD; Robinson BG; Eng C
    J Clin Endocrinol Metab; 1997 Nov; 82(11):3902-4. PubMed ID: 9360560
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Mutation analysis of the c-mos proto-oncogene and the endothelin-B receptor gene in medullary thyroid carcinoma and phaeochromocytoma.
    Eng C; Foster KA; Healey CS; Houghton C; Gayther SA; Mulligan LM; Ponder BA
    Br J Cancer; 1996 Aug; 74(3):339-41. PubMed ID: 8695346
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A new hot spot for mutations in the ret protooncogene causing familial medullary thyroid carcinoma and multiple endocrine neoplasia type 2A.
    Berndt I; Reuter M; Saller B; Frank-Raue K; Groth P; Grussendorf M; Raue F; Ritter MM; Höppner W
    J Clin Endocrinol Metab; 1998 Mar; 83(3):770-4. PubMed ID: 9506724
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Molecular and biochemical screening for the diagnosis and management of medullary thyroid carcinoma in multiple endocrine neoplasia type 2A.
    Vieira AE; Mello MP; Elias LL; Lau IF; Maciel LM; Moreira AC; Castro M
    Horm Metab Res; 2002 Apr; 34(4):202-6. PubMed ID: 11987030
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Multiple endocrine neoplasia type 2A with the identical somatic mutation in medullary thyroid carcinoma and pheochromocytoma without germline mutation at the corresponding site in the RET proto-oncogene.
    Akama H; Noshiro T; Kimura N; Shimizu K; Watanabe T; Shibukawa S; Nakai S; Miura W; Ito S; Miura Y
    Intern Med; 1999 Feb; 38(2):145-9. PubMed ID: 10225670
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Biological properties of Ret with cysteine mutations correlate with multiple endocrine neoplasia type 2A, familial medullary thyroid carcinoma, and Hirschsprung's disease phenotype.
    Ito S; Iwashita T; Asai N; Murakami H; Iwata Y; Sobue G; Takahashi M
    Cancer Res; 1997 Jul; 57(14):2870-2. PubMed ID: 9230192
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Unilateral surgery supported by germline RET oncogene mutation analysis in patients with sporadic medullary thyroid carcinoma.
    Miyauchi A; Matsuzuka F; Hirai K; Yokozawa T; Kobayashi K; Kuma S; Kuma K; Futami H; Yamaguchi K
    World J Surg; 2000 Nov; 24(11):1367-72. PubMed ID: 11038208
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Large-scale analysis of mutations in RET exon 16 in sporadic medullary thyroid carcinomas in Japan.
    Takano T; Miyauchi A; Yoshida H; Hasegawa Y; Kuma K; Amino N
    Jpn J Cancer Res; 2001 Jun; 92(6):645-8. PubMed ID: 11429053
    [TBL] [Abstract][Full Text] [Related]  

  • 52. De novo RET proto-oncogene mutation in a patient with multiple endocrine neoplasia type 2B.
    Chang TJ; Wu SL; Chang TC; Huang SH; Chang TJ
    J Formos Med Assoc; 1999 Oct; 98(10):692-7. PubMed ID: 10575840
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Ret-proto-oncogene analysis in medullary thyroid carcinoma.
    O'Keeffe DA; Hill AD; Sheahan K; Ryan F; Barton D; Fitzgerald RJ; McDermott EW; O'Higgins NJ
    Ir J Med Sci; 1998; 167(4):226-30. PubMed ID: 9868860
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Mutations of the RET proto-oncogene in the multiple endocrine neoplasia type 2 syndromes, related sporadic tumours, and hirschsprung disease.
    Eng C; Mulligan LM
    Hum Mutat; 1997; 9(2):97-109. PubMed ID: 9067749
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Point mutation of the RET proto-oncogene in the TT human medullary thyroid carcinoma cell line.
    Carlomagno F; Salvatore D; Santoro M; de Franciscis V; Quadro L; Panariello L; Colantuoni V; Fusco A
    Biochem Biophys Res Commun; 1995 Feb; 207(3):1022-8. PubMed ID: 7864888
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Germline and somatic mutations in an oncogene: RET mutations in inherited medullary thyroid carcinoma.
    Marsh DJ; Andrew SD; Eng C; Learoyd DL; Capes AG; Pojer R; Richardson AL; Houghton C; Mulligan LM; Ponder BA; Robinson BG
    Cancer Res; 1996 Mar; 56(6):1241-3. PubMed ID: 8640806
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Multiple endocrine neoplasia type 2 and RET: from neoplasia to neurogenesis.
    Hansford JR; Mulligan LM
    J Med Genet; 2000 Nov; 37(11):817-27. PubMed ID: 11073534
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The RET proto-oncogene in medullary and papillary thyroid carcinoma. Molecular features, pathophysiology and clinical implications.
    Komminoth P
    Virchows Arch; 1997 Jul; 431(1):1-9. PubMed ID: 9247627
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The oncogenic activity of RET point mutants for follicular thyroid cells may account for the occurrence of papillary thyroid carcinoma in patients affected by familial medullary thyroid carcinoma.
    Melillo RM; Cirafici AM; De Falco V; Bellantoni M; Chiappetta G; Fusco A; Carlomagno F; Picascia A; Tramontano D; Tallini G; Santoro M
    Am J Pathol; 2004 Aug; 165(2):511-21. PubMed ID: 15277225
    [TBL] [Abstract][Full Text] [Related]  

  • 60. 27-bp deletion in the ret proto-oncogene as a somatic mutation associated with medullary thyroid carcinoma.
    Kalinin V; Frilling A
    J Mol Med (Berl); 1998 Apr; 76(5):365-7. PubMed ID: 9587071
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.